Innovation Pharmaceuticals Inc (IPIX)

[farrell90]

From Basilea Pharmaceuticals 5/22/2022

It appears Brilacidin is on Basileas radar as an antibiotic. The new Brilacidin antifungal findings should only make Basilea more interested.

JMO

GLTA, Farrell

https://www.edisongroup.com/publication/renewed-focus-on-anti-infectives/30855/

"To increase focus and momentum in the anti-infective pipeline we expect Basilea to actively engage in licensing and/or transaction deals for further clinical-stage, anti-infective assets. Here, we envisage the company proceeding with licensing or the outright purchase of assets that are indicated against resistant bacteria/fungi and/or in Phase II or III and/or possess a novel mechanism of action. Examples of such assets are displayed in Exhibit 9. We note that these are examples that fit the above criteria but are however not to our knowledge current acquisition or licensing targets for Basilea.

Exhibit 9: Anti-infective assets currently in development

Asset


Company


Indication


Drug class


MOA


Market status

Afabicin


Debiopharm


ABSSSI, bone and joint infections


Benzofuran naphthyridine


Fatty acid synthesis inhibitor


Phase II

Brilacidin (iv)


Innovation Pharmaceuticals


MRSA infections, gram-negative infections.


Defensin mimetic


Host Defence Protein (HDP) regulator


Phase II

CRS3123


Crestone Inc.


Clostridium difficile infection


Diaryldiamine


Methionyl-tRNA synthetase inhibitor


Phase II

Zoliflodacin


Entasis Therapeutics


Gonorrhoea


Spiropyrimidinetrione


type II topoisomerase inhibitor


Phase III

Olorofim


F2G


Invasive aspergillosis
Coccidioidomycosis
Invasive moulds


Orotomide


dihydroorotate dehydrogenase inhibitor


Phase II

Source: Edison Investment Research, Evaluate Pharma

With the anticipated divestment of the oncology pipeline during CY22, we see deals of this kind as a potential near/mid-term value driver for Basilea, considering its experience in the area."